Results for peripheral translation from Swedish to English

peripheral arterial disease
atherothrombosis

pci (peripheral component interconnect)
peripheral component interconnect

of medicinal products for the treatment of peripheral arterial occlusive disease
1

note for guidance on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease:
note for guidance on clinical investigation of medicinal products for the treatment of peripheral arterial occlusive disease

resultat från ames/salmonella test och ”human peripheral blood lymphocyte (hpbl)” kromosomavvikelsetest visade ett positivt mutagent svar.
results of the ames/salmonella and human peripheral blood lymphocyte (hpbl) chromosome aberration tests showed a positive mutagenicity response.

den här sidan visar information om pci-bussen och installerade pci-kort, och andra enheter som använder peripheral component interconnect (pci)-bussen.
this page displays information about the pci-bus and installed pci cards, and other devices that use the peripheral component interconnect (pci) bus.

dokumenttitel note for guidance on clinical investigation of medicinal products for the treatment of diabetes mellitus note for guidance on clinical investigation of anti- depressive agents note for guidance on clinical investigation of medicinal products for pain treatment position paper on new modified formulations of acetyl salicylic acid in the secondary prevention of cardiovascular events note for guidance on clinical investigation of medicinal products for treatment of peripheral arterial occlusive disease concept paper on the revision of the note for guidance on evaluation of new anti- bacterial medicinal product (cpmp/ ewp/ 558/ 95) and the note for guidance on the pharmacodynamic section of the summary of product characteristics for antibacterial products points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications:
note for guidance on clinical investigation of medicinal products for treatment of peripheral arterial occlusive disease concept paper on the revision of the note for guidance on evaluation of new anti-bacterial medicinal product (cpmp/ ewp/ 558/ 95) and the note for guidance on the pharmacodynamic section of the summary of product characteristics for antibacterial products points to consider on biostatistical/ methodological issues arising from cpmp discussion on licensing applications: